BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 225 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,663,195 | +2728.5% | 745,666 | +1744.9% | 0.01% | – |
| Q2 2023 | $695,172 | +25.3% | 40,417 | +20.8% | 0.00% | – |
| Q1 2023 | $554,949 | +120.7% | 33,471 | +1.4% | 0.00% | – |
| Q4 2022 | $251,438 | -17.6% | 32,997 | +7.8% | 0.00% | – |
| Q3 2022 | $305,000 | +17.3% | 30,619 | +6.6% | 0.00% | – |
| Q2 2022 | $260,000 | -22.6% | 28,712 | -13.2% | 0.00% | – |
| Q1 2022 | $336,000 | -39.6% | 33,083 | -0.8% | 0.00% | – |
| Q4 2021 | $556,000 | -75.4% | 33,358 | -30.8% | 0.00% | -100.0% |
| Q3 2021 | $2,258,000 | -26.6% | 48,174 | -4.5% | 0.00% | -50.0% |
| Q2 2021 | $3,077,000 | +5.1% | 50,468 | +6.1% | 0.00% | 0.0% |
| Q1 2021 | $2,929,000 | -5.7% | 47,546 | +8.8% | 0.00% | 0.0% |
| Q4 2020 | $3,106,000 | +124.9% | 43,687 | +18.7% | 0.00% | +100.0% |
| Q3 2020 | $1,381,000 | +9.3% | 36,808 | -5.0% | 0.00% | 0.0% |
| Q2 2020 | $1,264,000 | +378.8% | 38,764 | +325.8% | 0.00% | – |
| Q1 2020 | $264,000 | – | 9,104 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |